Trial Profile
A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary) ; Irinotecan; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- 13 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Jun 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.